Product Development Progress - The company is advancing its antiviral product, Oseltamivir raw material and capsules, as planned [2] - The Ferrous Fumarate raw material has been approved for market launch in December 2025, aimed at preventing and treating iron deficiency anemia, thereby enriching the product pipeline [2] Financial Situation - On January 7, 2026, the company's main capital net inflow was 2.074 million yuan, indicating a shift from net outflow to net inflow compared to the previous trading day, suggesting a potential strengthening of short-term market sentiment [3] - A similar net inflow was observed on January 5, indicating a trend in capital movement [3] Company Fundamentals - For the first three quarters of 2025, the company achieved a revenue of 481 million yuan and a net profit attributable to shareholders of 91.9 million yuan, showing a year-on-year decline [4] - Investors should pay attention to the upcoming periodic financial reports for further insights [4] Industry Policy and Environment - The pharmaceutical and biotechnology industry has long-term development potential due to aging population and policy support, but individual stock performance may be influenced by industry policy dynamics and the company's own R&D investments [5]

Core Viewpoint - The company, Xintiandi (301277), has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used to prevent and treat iron deficiency anemia, enhancing its product portfolio and market competitiveness [1] Group 1 - The approval notification for Ferrous Fumarate is valid until December 7, 2030, indicating compliance with national drug registration requirements [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1] - The acquisition of this approval will enrich the company's product structure and enhance its market competitiveness [1]

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

Core Viewpoint - The company, New World (301277), has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used to prevent and treat iron deficiency anemia [1] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Listing Application Approval Notice" for Ferrous Fumarate [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1]